GT Biopharma Inc (GTBP)

[MagnumStocks]

Nice find! Thats back when this ticker was still OXIS. You can see that they have remained radically focussed on the finish line:

a therapy from GT Biopharma Inc. (OXISD) has turned some heads. Not only is the treatment cost-effective, it is also effective. GT Biopharma calls the therapy TriKE, which is short for trispecific killer engagers. TriKE offers a platform to target ligands that can be incorporated and has the ability to stimulate endogenous NK cells.

In short, this process can bypass the need for cell transfers altogether and make way for a new generation of immunotherapeutics. Dr. Daniel Vallera, director of the section on molecular cancer therapeutics at the University of Minnesota Cancer Center, and his team developed this treatment. He is also part of a group developing GT Biopharma’s OXS-1550.